Jacobs Levy Equity Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Jacobs Levy Equity Management’s Portfolio ALPN Stock Details ALPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,753	Closed	-$128K	–	1060
2022 Q3	$128K	Buy	+17,753	New	+$146K	﹤0.01%	954
2022 Q2	–	Sell	-138,279	Closed	-$1.24M	–	1113
2022 Q1	$1.24M	Buy	+138,279	New	+$1.2M	0.01%	724
2019 Q3	–	Sell	-21,274	Closed	-$90K	–	1015
2019 Q2	$90K	Buy	+21,274	New	+$123K	﹤0.01%	922
2017 Q3	–	Sell	-14,606	Closed	-$141K	–	1029
2017 Q2	$141K	Sell	14,606 -3,570	-20%	-$34.2K	﹤0.01%	876
2017 Q1	$212K	Buy	18,176 +10,600	+140%	+$107K	﹤0.01%	784
2016 Q4	$68K	Buy	+7,576	New	+$151K	﹤0.01%	927
2016 Q2	–	Sell	-5,026	Closed	-$84K	–	1245
2016 Q1	$84K	Buy	+5,026	New	+$101K	﹤0.01%	1048

Other funds holding ALPN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Jacobs Levy Equity Management's ALPN Position: Q4 2022 in Review

Jacobs Levy Equity Management sold out of Alpine Immune Sciences Inc (ALPN) in Q4 2022, closing a stake of 17,753 shares — an estimated $128K sold.

Jacobs Levy Equity Management first reported a position in ALPN in Q1 2016 and held it in 7 quarters. The position peaked at $1.24M in Q1 2022. 63 funds tracked by Wall St. Rank hold ALPN as of Q4 2022.

Jacobs Levy Equity Management reported no remaining Alpine Immune Sciences Inc position as of Q4 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 17,753 Alpine Immune Sciences Inc shares in Q4 2022, an estimated $128K.
Jacobs Levy Equity Management first reported a position in Alpine Immune Sciences Inc in Q1 2016 and held it in 7 quarters.
Jacobs Levy Equity Management's Alpine Immune Sciences Inc position peaked at $1.24M in Q1 2022.
63 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q4 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2022, filed 14 Feb 2023.